National Institute of Public Health and the Environment-RIVM, Bilthoven, The Netherlands.
Vaccine. 2012 Jul 27;30(35):5262-9. doi: 10.1016/j.vaccine.2012.05.060. Epub 2012 Jun 9.
Vaccination against influenza induces homologous as well as cross-specific hemagglutination inhibiting (HI) responses. Induction of cross-specific HI responses may be essential when the influenza strain does not match the vaccine strain, or even to confer a basic immune response against a pandemic influenza virus. We carried out a clinical study to evaluate the immunological responses after seasonal vaccination in healthy adults 18-60 years of age, receiving the yearly voluntary vaccination during the influenza season 2006/2007. Vaccinees of different age groups were followed for laboratory confirmed influenza (LCI) and homologous HI responses as well as cross-specific HI responses against the seasonal H1N1 strain of 2008 and pandemic H1N1 virus of 2009 (H1N1pdm09) were determined. Homologous HI titers that are generally associated with protection (i.e. seroprotective HI titers ≥40) were found in more than 70% of vaccinees. In contrast, low HI titers before and after vaccination were significantly associated with seasonal LCI. Cross-specific HI titers ≥40 against drifted seasonal H1N1 were found in 69% of vaccinees. Cross-specific HI titers ≥40 against H1N1pdm09 were also significantly induced, especially in the youngest age group. More specifically, cross-specific HI titers ≥40 against H1N1pdm09 were inversely correlated with age. We did not find a correlation between the subtype of influenza which was circulating at the age of birth of the vaccinees and cross-specific HI response against H1N1pdm09. These data indicate that the HI titers before and after vaccination determine the vaccination efficacy. In addition, in healthy adults between 18 and 60 years of age, young adults appear to be best able to mount a cross-protective HI response against H1N1pdm09 or drifted seasonal influenza after seasonal vaccination.
接种流感疫苗可诱导同源和交叉特异性血凝抑制(HI)反应。当流感毒株与疫苗株不匹配时,甚至为了对大流行性流感病毒产生基本免疫反应,诱导交叉特异性 HI 反应可能是必要的。我们进行了一项临床研究,以评估在 2006/2007 年流感季节接受年度自愿疫苗接种的 18-60 岁健康成年人接种季节性疫苗后的免疫反应。不同年龄组的接种者接受了实验室确诊的流感(LCI)以及针对 2008 年季节性 H1N1 株和 2009 年大流行性 H1N1 病毒(H1N1pdm09)的同源 HI 反应和交叉特异性 HI 反应的随访。发现大多数疫苗接种者的同源 HI 滴度(即与保护相关的血清保护性 HI 滴度≥40)均超过 70%。相比之下,接种前后低的 HI 滴度与季节性 LCI 显著相关。发现 69%的疫苗接种者对漂移的季节性 H1N1 具有≥40 的交叉特异性 HI 滴度。对 H1N1pdm09 的交叉特异性 HI 滴度也明显诱导,尤其是在年龄最小的年龄组中。更具体地说,对 H1N1pdm09 的交叉特异性 HI 滴度≥40 与年龄呈负相关。我们没有发现疫苗接种者出生时流行的流感亚型与针对 H1N1pdm09 的交叉特异性 HI 反应之间存在相关性。这些数据表明,接种前后的 HI 滴度决定了疫苗接种的效果。此外,在 18-60 岁的健康成年人中,年轻成年人似乎最能够在季节性疫苗接种后针对 H1N1pdm09 或漂移的季节性流感产生交叉保护的 HI 反应。